SCHEMBL3276127

SCHEMBL3276127

CCOc1ccc(C(=CCSc2ccc(OCC(=O)O)c(I)c2)c2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 11/20 0.57
PPARA Q07869 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.41
GLA P06280 1/20 0.41
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
PPARG P37231 3/20 0.39
FFAR1 O14842 1/20 0.39
ESR1 P03372 2/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP19A1 P11511 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269875 1.00 PPARD (0.57) PPARDPPARAL3MBTL1GLALMNA
SCHEMBL3269463 0.97 PPARD (0.60) PPARDPPARAL3MBTL1GLAPPARG
SCHEMBL3269445 0.92 PPARD (0.52) PPARDPPARAL3MBTL1GLALMNA
SCHEMBL3275585 0.92 PPARD (0.52) PPARDPPARAL3MBTL1GLALMNA
SCHEMBL3270411 0.91 PPARD (0.58) PPARDPPARALMNAKMT2A
SCHEMBL3270413 0.91 PPARD (0.58) PPARDPPARALMNAKMT2A
SCHEMBL3271616 0.90 PPARD (0.52) PPARDPPARAL3MBTL1GLALMNA
SCHEMBL3268745 0.89 PPARD (0.72) PPARDPPARAPPARG
SCHEMBL3271954 0.89 PPARD (0.72) PPARDPPARAPPARG
SCHEMBL3270701 0.89 PPARD (0.58) PPARDPPARAL3MBTL1GLAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558572-B1 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2010-06-30 EP claimed
US-7129268-B2 Peroxisome proliferator activated receptor-active arylene acetic acid derivatives NOVO NORDISK A/S (DK) 2006-10-31 US claimed
EP-1558572-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2005-08-03 EP claimed
US-20050070583-A1 Novel compounds, their preparation and use VTVX HOLDINGS II LLC 2005-03-31 US claimed
WO-2004037776-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2004-05-06 WO claimed
EP-1558572-B1 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2010-06-30 EP disclosed
US-7129268-B2 Peroxisome proliferator activated receptor-active arylene acetic acid derivatives NOVO NORDISK A/S (DK) 2006-10-31 US disclosed
EP-1558572-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2005-08-03 EP disclosed
US-20050070583-A1 Novel compounds, their preparation and use VTVX HOLDINGS II LLC 2005-03-31 US disclosed
WO-2004037776-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070583-A1 Novel compounds, their preparation and use PPARG, PPARD, PPARA PPARD 2/4885PPARA 3/4885L3MBTL1 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.